OVID — Ovid Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1636651 ·
Last close
$2.22
Market Cap
$418.98M
52W High
$3.11
52W Low
$1.21
ADV30
2,293,110
Next earnings
2026-11-10
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 733,000 — -15,698,000 -15,009,000 231,973,000 11,327,000 22,083,000
Mar 2026 0 — -17,846,000 -16,988,000 225,628,000 94,064,000 27,359,000
Dec 2025 718,000 — -12,293,000 9,663,000 150,934,000 13,153,000 20,274,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-57,778,000
Investing CF
$-141,701,000
Financing CF
$193,040,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.24
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-374,490,000
Inventory
—
Receivables
—
ST Investments
$122,790,000
EBIT TTM
$-68,201,000
Pretax Income TTM
$-43,114,000
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,453,000
EBITDA
$-68,117,000
Free Cash Flow
$-34,771,000
Enterprise Value
$355,132,064
Total Cash
$136,600,992
Total Debt
$12,354,000
Shares Out
188,731,914
Trailing EPS
$-0.15
Book Value
$1.05
ROE
-35.4%
ROA
-29.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,252,000 -42,439,000 -17,414,000 150,934,000 20,274,000 130,660,000 -38,334,000
Dec 2024 566,000 -61,885,000 -26,433,000 92,167,000 23,941,000 68,226,000 -55,956,000
Dec 2023 392,000 -59,281,000 -52,339,000 144,027,000 56,229,000 87,798,000 -45,781,000
Dec 2022 1,502,748 -55,547,651 -54,169,029 155,265,814 22,993,250 132,272,564 -55,227,127
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$1,583,000
NetIncome TTM
$-34,492,000
OpCashFlow TTM
—
Assets (Latest)
$231,973,000
Forward EPS
$-0.40

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $2.26 · call oi: 4,424 · put oi: 206
Expected Move to 2027-01-15: ±$0.82 (36.50%) — implied range $1.43 – $3.08 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
OCS Oculis Holding AG $417.01M $7.51 —
CTMX CytomX Therapeutics, Inc. $422.93M $1.94 —
PRTA PROTHENA CORP PUBLIC LTD CO $424.15M $8.26 —
AVTX Avalo Therapeutics, Inc. $412.28M $7.13 —
PTCHF PureTech Health plc $405.77M $1.65 —

News headlines (Yahoo Finance, 1h cache)

Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
2026-11-10 12:00 · Yahoo
Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-11-05 13:00 · Yahoo
Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329
2026-10-08 09:13 · Yahoo
Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
2026-08-18 16:00 · Yahoo
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
2026-08-13 12:30 · Yahoo
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
2026-08-05 14:00 · Yahoo
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer
2026-07-14 10:33 · Yahoo
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
2026-07-08 11:00 · Yahoo
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely
2026-05-14 10:51 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.